Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis

OBJECTIVE: To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD). METHODS: A systematic literature search was conducted to identify randomised controlled trials (...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Zhang, Xiulan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199620/
https://www.ncbi.nlm.nih.gov/pubmed/25330364
http://dx.doi.org/10.1371/journal.pone.0109744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199620/
https://www.ncbi.nlm.nih.gov/pubmed/25330364
http://dx.doi.org/10.1371/journal.pone.0109744

Ejemplares similares